Assessment of the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients
© 2022 Suleyman Baldane et al., published by Sciendo..
Objective. This study was aimed to evaluate the prevalence of Cushing's syndrome and the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients. Methods. Anthropometric measurements and other laboratory data, including 1 mg dexamethasone suppression test of 753 class 3 obese patients, who applied to the Endocrinology and Metabolism Outpatient Clinic for the pre-bariatric surgery evaluation between 2011 and 2020, were evaluated retrospectively. Results. An abnormal response to the 1 mg dexamethasone suppression test (cortisol ≥1.8 mcg/dl) was observed in 24 patients and the presence of Cushing's syndrome was confirmed by additional tests in 6 patients. The prevalence of abnormal dexamethasone suppression test was 3.18% and the prevalence of Cushing's syndrome 0.79%. The specificity value was determined as 97.5% for 1 mg dexamethasone suppression test with cortisol threshold value ≥1.8 mcg/dl. Conclusions. The prevalence of Cushing's syndrome was found to be low in class 3 obese patients and 1 mg of dexamethasone suppression test had a very sufficient performance for Cushing's syndrome screening in this patient group.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
---|---|
Enthalten in: |
Endocrine regulations - 56(2022), 4 vom: 01. Okt., Seite 265-270 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Baldane, Suleyman [VerfasserIn] |
---|
Links: |
---|
Themen: |
7S5I7G3JQL |
---|
Anmerkungen: |
Date Completed 25.10.2022 Date Revised 25.10.2022 published: Electronic-Print Citation Status MEDLINE |
---|
doi: |
10.2478/enr-2022-0028 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM347849539 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM347849539 | ||
003 | DE-627 | ||
005 | 20231226034817.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2478/enr-2022-0028 |2 doi | |
028 | 5 | 2 | |a pubmed24n1159.xml |
035 | |a (DE-627)NLM347849539 | ||
035 | |a (NLM)36270344 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Baldane, Suleyman |e verfasserin |4 aut | |
245 | 1 | 0 | |a Assessment of the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.10.2022 | ||
500 | |a Date Revised 25.10.2022 | ||
500 | |a published: Electronic-Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2022 Suleyman Baldane et al., published by Sciendo. | ||
520 | |a Objective. This study was aimed to evaluate the prevalence of Cushing's syndrome and the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients. Methods. Anthropometric measurements and other laboratory data, including 1 mg dexamethasone suppression test of 753 class 3 obese patients, who applied to the Endocrinology and Metabolism Outpatient Clinic for the pre-bariatric surgery evaluation between 2011 and 2020, were evaluated retrospectively. Results. An abnormal response to the 1 mg dexamethasone suppression test (cortisol ≥1.8 mcg/dl) was observed in 24 patients and the presence of Cushing's syndrome was confirmed by additional tests in 6 patients. The prevalence of abnormal dexamethasone suppression test was 3.18% and the prevalence of Cushing's syndrome 0.79%. The specificity value was determined as 97.5% for 1 mg dexamethasone suppression test with cortisol threshold value ≥1.8 mcg/dl. Conclusions. The prevalence of Cushing's syndrome was found to be low in class 3 obese patients and 1 mg of dexamethasone suppression test had a very sufficient performance for Cushing's syndrome screening in this patient group | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Cushing’s syndrome | |
650 | 4 | |a dexamethasone suppression test | |
650 | 4 | |a obesity | |
650 | 4 | |a screening | |
650 | 7 | |a Hydrocortisone |2 NLM | |
650 | 7 | |a WI4X0X7BPJ |2 NLM | |
650 | 7 | |a Dexamethasone |2 NLM | |
650 | 7 | |a 7S5I7G3JQL |2 NLM | |
700 | 1 | |a Celik, M |e verfasserin |4 aut | |
700 | 1 | |a Kebapcilar, Levent |e verfasserin |4 aut | |
700 | 1 | |a Ipekci, Suleyman Hilmi |e verfasserin |4 aut | |
700 | 1 | |a Abusoglu, Sedat |e verfasserin |4 aut | |
700 | 1 | |a Yilmaz, Huseyin |e verfasserin |4 aut | |
700 | 1 | |a Alptekin, Husnu |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Endocrine regulations |d 1995 |g 56(2022), 4 vom: 01. Okt., Seite 265-270 |w (DE-627)NLM012655317 |x 1336-0329 |7 nnns |
773 | 1 | 8 | |g volume:56 |g year:2022 |g number:4 |g day:01 |g month:10 |g pages:265-270 |
856 | 4 | 0 | |u http://dx.doi.org/10.2478/enr-2022-0028 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 56 |j 2022 |e 4 |b 01 |c 10 |h 265-270 |